In today’s Pharmaceutical Executive Daily, a new a is expected to evolve in 2026, the FDA rejects AstraZeneca’s application for a subcutaneous indication of Saphnelo, and SanegeneBio enters a $1 billion global licensing agreement with Genentech focused on RNAi development.

Pharmaceutical Executive Daily: SanegeneBio's $1.5 Billion License Agreement with Genentech

<div>The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and <a href="http://PharmExec.com">PharmExec.com</a> to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry. </div>

Science

Life Sciences

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and PharmExec.com to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.

The Pharm Exec Podcast goes beyond the pages of the Pharmaceutical Executive print magazine and <a href="http://PharmExec.com" rel="noopener noreferrer">PharmExec.com</a> to bring the latest commercial insights to the C-suite through in-depth interviews. Podcast episodes examine current trends, key conferences, and critical topics in the industry.&nbsp;

Share Pharmaceutical Executive Daily: SanegeneBio's $1.5 Billion License Agreement with Genentech

Sign up to save your podcasts

Pharmaceutical Executive Daily: SanegeneBio's $1.5 Billion License Agreement with Genentech

Pharmaceutical Executive Daily: SanegeneBio's $1.5 Billion License Agreement with Genentech

More shows like Pharmaceutical Executive

Planet Money

Economist Podcasts

Motley Fool Money

WSJ Your Money Briefing

WSJ What’s News

Bloomberg Businessweek

WSJ Tech News Briefing

HBR IdeaCast

Bold Names

The Indicator from Planet Money

The Readout Loud

Thoughts on the Market

The Journal.

Bloomberg Daybreak: US Edition

WSJ's Take On the Week